Baxter exec shake-up?
This article was originally published in The Gray Sheet
Executive Summary
VP-Investor Relations Neville Jeharajah, 51, will retire June 30 after 22 years with Baxter, the Deerfield, Ill. firm announces June 7. IR Director Mary Kay Ladone will serve as the primary contact between Baxter and the investment community on an interim basis. The move may portend further executive changes for the company as new CEO Robert Parkinson molds Baxter's senior management (1"The Gray Sheet" April 26, 2004, p. 16). The firm has no timetable for replacing Jeharajah...
You may also be interested in...
“Realistic” CEO Parkinson Will Lead Baxter Through Continued Restructuring
Baxter's decision to tap former Abbott exec Robert Parkinson as chairman and CEO sets the stage for swift operational reforms at the highly diversified firm
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.